A real-world study on diagnosis and prognosis of light-chain cardiac amyloidosis in Southern China,BMC Cardiovascular Disorders

当前位置： X-MOL 学术 › BMC Cardiovasc. Disord. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

A real-world study on diagnosis and prognosis of light-chain cardiac amyloidosis in Southern China
BMC Cardiovascular Disorders ( IF 2.0 ) Pub Date : 2021-09-18 , DOI: 10.1186/s12872-021-02256-3
Zhijian Wu ₁ , Muzheng Li ₁ , Tudahun Ilyas ₁ , Wei Li ₂ , Mu Zeng ₃ , Fang Li ₄ , Yanxia Liu ₁ , Mingxian Chen ₁ , Yaqin Chen ₁ , Qingyi Zhu ₁ , Nenghua Qi ₁ , Qiming Liu ₁ , Jianjun Tang ₁

Affiliation

Light-chain cardiac amyloidosis (AL-CA) has been highly valued in developed countries, but in developing countries, the recognition and diagnosis of this condition is still limited. There are currently few reports on a large number of Chinese patients with AL-CA. The present study aimed to report real-world clinical characteristics and prognosis of AL-CA in China. Consecutive patients with AL-CA diagnosed at the Second Xiangya Hospital of Central South University between June 2012 and September 2020 were reviewed. A total of 170 patients with AL-CA have been recruited, whose mean ages were 60.81 ± 10.46. 70.59% of the patients were male. They were from eight provinces in southern China, 55.7% were referred patients, and 37.3% had been misdiagnosed previously. 64 (37.6%) patients received chemotherapy. The median survival time for patients with AL-CA was 8.00 months, and survival time for patients who received chemotherapy was 13.00 months, which was significantly longer than that of patients with palliative treatment (13.00 vs 6.00, p = 0.004). Although clinicians have improved their understanding of AL-CA in recent years, the prognosis of AL-CA is still poor, and the misdiagnosis rate and missed diagnosis rate are still very high in China. It is imperative to improve the recognition and early diagnosis of this condition, which may require multidisciplinary collaboration among cardiologists, hematologists and nephrologists.

更新日期：2021-09-19

点击分享查看原文

点击收藏

公开下载

阅读更多本刊最新论文本刊介绍/投稿指南11